WO1984003506A1 - Antigenically active amino acid sequences - Google Patents

Antigenically active amino acid sequences Download PDF

Info

Publication number
WO1984003506A1
WO1984003506A1 PCT/AU1984/000038 AU8400038W WO8403506A1 WO 1984003506 A1 WO1984003506 A1 WO 1984003506A1 AU 8400038 W AU8400038 W AU 8400038W WO 8403506 A1 WO8403506 A1 WO 8403506A1
Authority
WO
WIPO (PCT)
Prior art keywords
sequences
replaced
amino acid
peptide
foot
Prior art date
Application number
PCT/AU1984/000038
Other languages
French (fr)
Inventor
Hendrik Mario Geysen
Original Assignee
Commw Serum Lab Commission
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commw Serum Lab Commission filed Critical Commw Serum Lab Commission
Priority to DE8484900954T priority Critical patent/DE3485972T2/en
Priority to AT84900954T priority patent/ATE82018T1/en
Priority claimed from AU25428/84A external-priority patent/AU573574B2/en
Publication of WO1984003506A1 publication Critical patent/WO1984003506A1/en
Priority to NO844295A priority patent/NO167745C/en
Priority to DK532184A priority patent/DK171118B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • This invention relates to the identification and chemical synthesis of peptides (or amino acid sequences) which constitute the immunogenic determinant (s) of an immunologically important coat protein, VP1, of foot-and-mouth disease virus, and to the use of these peptides for example, in the production of vaccines and diagnostic reagents.
  • immunogenic determinant(s) for biologically important proteins is regarded as being of particular importance since, once these determinants have been identified, they can be simply and economically synthesised so as to provide the desired peptide sequences for use in vaccines which will have a high degree of specificity, and which will avoid any undesired effects from unnecessary amino acid or peptide sequences which might still be present in, for example, sub-unit type vaccines.
  • the immunogenicity of a polypeptide can be defined as the immune response directed against a limited number of immunogenic determinants, which are confined to a few loci on the polypeptide molecule, (see Crumpton, M.J., in The Antigens (ed. Sela, M., Academic Press, New York, 1974); Benjamini, E. et al. , Curr. Topics Microbiol. Immunol. 58, 85-135 (1972); and Atassi, M.Z., Immunochemistry 12, 423-438 (1975).) Antisera prepared against chemically synthesized peptides corresponding to short linear stretches of the polypeptide sequence have been shown to react well with the whole polypeptide, (see Green, N. et al., Cell 28, 477-487 (1982); Bittle, J.L. et al.. Nature 298, 30-33 (1982); Dreesman et al.,
  • a determinant can consist of a single sequence, (continuous), or of several sequences (discontinuous) brought together from linearly distant regions of the polypeptide chain by the folding of that chain as it exists in the native state, (see Atassi, M.Z., Immunochemistry 15, 909-936 (1978).).
  • the size of a contributing element can then vary between one and the maximum number of amino acids consistent with the dimensions of the antibody combining site, and is likely to be of the order of five to six, (see Atassi, M.Z., supra). Any systematic mapping of all the detectable antigenic elements of a polypeptide by the chemical synthesis of overlapping segments and measurement of their subsequent reactivity with antisera prepared against the native protein has until now been severely limited by the scale of the synthetic and testing capability required, (see
  • the FMD virus which belongs to the aphthovirus genus of the family Picornaviridae, consists of an ordered aggregation of structurally independent sub-units surrounding a molecule of infectious single-stranded RNA. Under relatively mild conditions the whole particle readily dis-aggregates to give the naked RNA, 60 copies of the VP4 polypeptide, and 12 sub-units consisting of an ordered arrangement of five copies of each of the polypeptides, VP1, VP2 and VP3. Each of these structural sub-units can be further disrupted to yield the isolated component proteins.
  • the VP1 protein of FMD virus has been shown to be an immunologically important coat protein of the virus.
  • a preferred method for solid-phase synthesis according to the present invention comprises the use of a polymeric material such as polyethylene or polypropylene as the solid-phase carrier, onto which is graft polymerised a vinyl monomer containing at least one functional group to produce polymeric chains on the carrier.
  • the functional groups of these polymeric chains are then reacted to provide primary or secondary amino groups of the chains, and these amino groups are then sequentially reacted with amino acid residues in appropriate order so as to build up a desired synthetic peptide.
  • the carrier is preferably in the form of a solid polymer rod having a diameter of about 4mm and a length of about 50mm. A number of such rods can be held in a suitable holder in a 12 x 8 grid whose dimensions correspond to those of the standard microtitre plate used for enzyme-linked immunosorbent assays (ELISA).
  • the present invention provides a synthetic peptide which displays the antigenicity of the VP1 protein of foot-and-mouth disease virus, characterised in that at least a portion of said peptide is selected from the group consisting of five-, six- or seven-long antigenically active amino acid sequences of said VP1 protein, and antigenically active modified sequences (as hereinafter defined) thereof.
  • a synthetic peptide which displays the antigenicity of the VP1 protein of foot-and-mouth disease virus, Type O 1 , characterised in that at least a portion of said peptide is selected from amino acid sequences of the group consisting of:
  • a synthetic peptide which displays the antigenicity of the VP1 protein of foot-and-mouth disease virus, type A 10 (A 61 ), characterised in that at least a portion of said peptide is selected from amino acid sequences of the group consisting of:
  • a synthetic peptide which displays the antigenicity of the VP1 protein of foot-and-mouth disease virus, type C1, characterised in that at least a portion of said peptide is selected from amino acid sequences of the group consisting of:
  • antigenically active modified sequences is used to describe sequences of amino acids which are based on any one of sequences (i) to (iv) of the first, second or third aspects of the invention as described above, but in which one of the amino acids in the said sequence is replaced by another amino acid to provide a modified sequence which is antigenically active.
  • Antigenically active modified sequences in accordance with the first aspect of this invention include hexapeptide sequences based on the formula:
  • G at position (1) is replaced by A, H, I, K, M,
  • N, P, Q, S or T or D at position (2) is replaced by A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V or Y; or
  • N, S or R; or V at position (5) is replaced by A, D, E, F, I, K, L, M, N, Q, R, S, T or Y.
  • Antigenically active modified sequences in accordance with the second aspect of this invention include hexapeptide sequences based on the formula:
  • G at position (1) is replaced by A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; or D at position (2) is replaced by L; or
  • I at position (6) is replaced by A, C, D, E, F, K, L, M, Q, R, S, T, V, W or Y.
  • Antigenically active modified sequences in accordance with the third aspect of this invention include hexapeptide sequences based on the formula:
  • D at position (1) is replaced by H or V;
  • H at position (4) is replaced by A, C, D, E, F,
  • the peptides of the present invention are characterised in that at least a portion of the peptide contains an amino acid sequence selected from the groups (i) to (v) described above. Tests which have been carried out, particularly utilising the ELISA technique, have established the activity of these amino acid sequences by their reactivity with antisera. It should be noted, however, that whilst the synthetic peptides of this invention may comprise sequences which are only 5, 6 or 7 amino acids long, the present invention also extends to synthetic peptides in which one or more additional amino acids are included on either or both ends of the defined sequence, that is either on the carboxyl (-COOH) end or on the amino (-NH 2 ) end or both. While such additional amino acids may not play any direct role in enhancing the immunogenic activity of the defined amino acid sequence, they may act, for example, as spacer amino acids to space the antigenically active amino acid sequence from the free carboxyl and/or free amino ends of the sequence.
  • the modified sequences in accordance with this invention have been similarly synthesised and tested utilising the ELISA technique. As previously described, each of these modified sequences was derived by replacing one amino acid in the original sequence by another amino acid.
  • the peptides of the present invention can be chemically synthesized from their constituent amino acids. This synthesis may be carried out, for example, by the Merrifield solid-phase method, as described in J.A.C.S. 85: 2149-2154 (1963). In the Merrifield solid-phase method, the C-terminal amino acid is attached to chloromethylated polystyrene-divinylbenzene copolymer beads. Each subsequent amino acid, with a suitable protecting group if necessary, is then added sequentially to the growing chain. As described in the Merrifield article, the protective group may be, for example, a t-butyloxycarbonyl or carbobenzoxy group.
  • the desired amino acid sequence and chain length can be produced.
  • the protective group is removed from N-terminal amino acid, and the C-terminal amino acid is cleaved from the supporting beads, using a suitable reagent such as trifluoroacetic acid and hydrogen bromide.
  • the synthesis can be carried out by the solid-phase method, in which the synthetic peptide structure is built up on a solid-phase carrier which comprises a polymeric material, for example a polyethylene rod or pin, having a vinyl monomer graft polymerised thereto, for example by ⁇ -radiation of acrylic acid, acrylonitrile or acrylamide monomers.
  • a mono- protected biamine such as lysine or lysine-alanine is then reacted with the polymeric chain formed on the solid-phase carrier and the synthetic peptide then built up by sequential reaction of amino acids in the same manner as in the Merrifield method described above.
  • the final step in both the methods referred to above is the removal of the synthetic peptide from the solid-phase carrier or support by a cleaving reaction using a suitable reagent
  • a suitable reagent for some uses of the peptides of the present invention it is convenient if not essential for the chemically synthesized peptides to be used in the form of a product in which the peptide is coupled or linked to a solid-phase carrier or support.
  • the final cleaving step is omitted.
  • Such antigenically active, chemically synthesized peptides which are immobilised on a solid-phase carrier or support are of particular utility in the performance of immunochemical assays, such as enzyme immunoassays (EIA).
  • the immunogenic synthetic peptides of the present invention may provide the basis upon which the formation of synthetic vaccines against foot-and-mouth disease virus can be developed.
  • Such synthetic vaccines would have particular merit insofar as they could be manufactured so as to be free of amino acid sequences corresponding to the entire amino acid sequences of the viral protein, and also free of biologically produced materials and of active or inactivated viral residues.
  • the use of synthetic peptides as the basis for vaccines is discussed, for example, by Beale, J. in Nature 298 14-15 (1982), and by Sutcliffe, J.G. et al in Science, 219, 660-666 (1982).
  • the synthetic peptides of the present invention could be used either alone, in combination, and/or in association with a physiologically acceptable carrier and/or adjuvant.
  • the synthetic peptides of the present invention also have potential for use in a number of other applications in the immunological field, including use in diagnostic and other immunological testing procedures, particularly in immunochemical assays such as enzyme immunoassays.
  • N ⁇ -t-Butyloxycarbonyl-L-Lysine methyl ester was coupled to the polyethylene polyacrylic acid (PPA) via the N -amino group of the side-chain. This was followed by the coupling of Boc-Alanine, to complete a peptide-like spacer. Amino-substitution of the support was determined by reacting NH 2 -Lysine(OMe)-PPA with C 14 labelled butyric acid, and was found to be 8-10 nmoles/rod.
  • side-chain protecting groups were used; O-benzyl for threonine, serine, aspartic acid, glutamic acid and tyrosine; carbobenzoxy for lysine; tosyl for arginine; 4-methyl benzyl for cysteine and 1-benzyloxycarbonylamido-2,2,2,-trifluoroethyl for histidine.
  • Side-chain deprotection was achieved by treatment with borontris (trifluoracetate) in trifluoroacetic acid for 90 minutes at room temperature (see Pless, J., Bauer, W., Angewante Chemie 85, 142 (1973)).
  • the enzyme-linked immunosorbent assay was used to test each rod-coupled peptide (RCP) for reactivity with each of the defined antisera described above.
  • RCPs were pre-coated with 10% horse serum, 10% ovalbumin and 1% Tween-80 in PBS, to block non-specific absorption of antibodies, for 1 hour at 37°C. Overnight incubation at 4°C in antiserum diluted 1/40 in the preincubation mixture, was followed by 3 washes in 0.05% Tween-80/PBS. Reaction for 1 hour at 37°C with the appropriate anti-rabbit
  • IgG immunoglobulin coupled to horse radish peroxidase was again followed by extensive washing in PBS/Tween to remove excess conjugate.
  • the presence of antibody was detected by reaction for 45 min with a developing solution (40 mg orthophenylenediamine, 20 ⁇ l of hydrogen peroxide in 100 ml of phosphate buffer, pH 5.0), and the colour produced read in a Titertek Multiscan at 420 nm.
  • peptides were washed three times at 37°C in 8M urea containing 0.1% 2-mercaptoethanol and 0.1% sodium dodecyl sulphate, followed by several washes in PBS to remove all traces of bound antibody. The RCPs were then ready for further testing with different antisera.
  • Anti-intact virus particle sera were prepared by immunising rabbits with 50 ⁇ g of inactivated, purified virus in complete Freund's adjuvant. The animals were bled 3-4 weeks after the single vaccination. Anti-virus-subunit serum (rabbit) was prepared by immunizing 3 times, 3-4 weeks apart, with 10 ⁇ g of acid-disrupted purified virus, initially in complete Freund's and subsequently in incomplete Freund's adjuvant. The polypeptide VP1 was separated from the mixture of proteins obtained from urea disrupted, purified virus, by iso-electric focusing. (see
  • scans (a) and (b) show the extremes in the reactivity patterns found. Large quantitative differences in the response to an identical antigen preparation have been reported before, however, these scans highlight the variability possible in the antibody composition between sera. From an examination of scans (a), (b) and (c), antibody reactive with peptides numbers 146 and 147 are present in whole anti-intact virus sera, but absent after absorption with purified virus. These same antibodies are not observed in the anti-subunit sera, scan (d), and only weakly present in the anti-VP1 sera, scan (e).
  • the active element is five amino acids long, i.e. the sequence common to both Asp-Leu-Gln-Val-Leu (D - L Q - V - L); or two, that the active element is seven amino acids long, i.e. the combination of the two hexapeptides Gly-Asp-Leu-Gln-Val-Leu-Ala (G - D - L Q - V - L - A).
  • Gly-Asp-Leu-Gly-Ser-Ile (G - D - L - G - S - I) and Asp-Leu-Gly-Ser-Ile-Ala (D - L - G - S - I - A) are the principal loci for the antigenic determinant of the A-type of FMDV.
  • Example 1 The synthesis method of Example 1 was used to synthesize 120 hexapeptides, each consisting of five original amino acids of the antigenic hexapeptide G D - L - Q - V- L (type O 1 ), the other amino acid being systematically replaced with each of the 20 possible naturally occurring genetically coded amino acids. This replacement was performed at each of the six positions in the peptide in turn.
  • the 120 peptides comprised six copies of the original sequence and 114 variations of the original sequence, each of the 114 variations differing in only one amino acid from the original sequence. This strategy is illustrated diagrammatically in Fig.5.
  • Every group of twenty lines corresponds to the complete replacement set for one of the six N-terminal residue positions in the hexapeptide G D - L - Q - V - L. It can be seen that the amino acids at certain positions in the sequence can be readily replaced without loss of antigenicity, whereas other positions cannot accept replacement without partial or complete loss of antigenicity. Those peptides containing replacements which result in retained antigenicity are candidates for use in vaccine manufacture.
  • the selected antigenic peptides of each of the three FMDV types were synthesized with a variety of linking amino acids at the N-terminal end and with the linking amino acid lysine at the C-terminal end.
  • the amino acids in the links do not occur in those positions in the native sequences.
  • the synthesized peptides were coupled to a protein carrier and combined with an adjuvant for the purpose of animal immunisation.
  • the carrier was keyhole limpet hemocyanin (KLH) and the adjuvant was either an oil adjuvant or aluminium hydroxide gel.
  • Table 2 gives the results of serological tests on immunised rabbits. It shows that in each case the rabbit produced a significant amount of antibody able to react with FMDV and able to neutralise the infectivity of FMDV.
  • a protection test was carried out using guinea pigs as a model, since guinea pigs are susceptible to infection with FMDV.
  • the peptide used for immunisation was C - G - D - L - Q - V - L - A - K, which is made up of the heptapeptide G - D - L - Q V - L - A from FMDV type O 1 (residues 146-152), a cysteine linker at the N-terminal end and a lysine linker at the C-terminal end.
  • the peptide was coupled to KLH using maleimidobenzoyl N-hydroxysuccinimide ester, which links the peptide to the KLH via the cysteine side chain.
  • the KLH-peptide conjugate was then absorbed to an aluminium hydroxide gel and used to vaccinate the guinea pigs at a dose of 100 ⁇ g peptide per animal.
  • An unvaccinated group of guinea pigs served as controls. The animals were challenged 21 days after the single vaccination.
  • Fig.2 An example of the application of the present invention for diagnostic use is drawn from Fig.2. This shows that ELISA testing using support-coupled peptides (SCPs) is an extremely strain-specific tool for detecting FMDV antibodies.
  • SCPs support-coupled peptides
  • Whole antisera to FMDV type O 1 reacted with hexapeptides 146, 147 and 206 derived from the FMDV type O 1 sequence, whereas antiserum to type C 1 did not react at all.
  • Control testing on the antiserum to FMDV type C 1 showed that, likewise, specific reaction only occurred with peptides derived from the C 1 sequence.
  • Testing of the SCPs with other non-FMDV-specific control sera, and hyperimmune sera to other FMDV types has also shown that no reaction occurs.

Abstract

A synthetic peptide which displays the antigenicity of the VP1 protein of foot-and-mouth disease virus, characterised in that at least a portion of said peptide is selected from the group consisting of five-, six- or seven-long antigenically active amino acid sequences of said VP1 protein, and antigenically active modified sequences thereof.

Description

"ANTIGENICALLY ACTIVE AMINO ACID SEQUENCES"
This invention relates to the identification and chemical synthesis of peptides (or amino acid sequences) which constitute the immunogenic determinant (s) of an immunologically important coat protein, VP1, of foot-and-mouth disease virus, and to the use of these peptides for example, in the production of vaccines and diagnostic reagents.
In the search for more effective means of protection against infective disease in man and animals, major advances have been made in the last decade. It is now clear that immunization is possible using an isolated component of the whole causative agent, such as for example in the influenza virus sub-unit vaccines.
Current efforts are directed at reducing the scale of the immunizing component still further, first to the polypeptide (protein) carrying the necessary trigger for the immune system and secondly to the trigger itself. Recombinant DNA technology has provided the means, by translation from the determined nucleotide sequences, of obtaining reliable amino acid sequences for biologically important proteins including such proteins which were not readily available from natural sources. However, methods for identifying the loci of a protein which constitute the trigger(s) or immunogenic determinant(s) are few and very time consuming and form the bottle neck to further rapid progress.
The determination of the immunogenic determinant(s) for biologically important proteins, particularly proteins derived from the causative agents of infective disease in man and animals, is regarded as being of particular importance since, once these determinants have been identified, they can be simply and economically synthesised so as to provide the desired peptide sequences for use in vaccines which will have a high degree of specificity, and which will avoid any undesired effects from unnecessary amino acid or peptide sequences which might still be present in, for example, sub-unit type vaccines.
The immunogenicity of a polypeptide can be defined as the immune response directed against a limited number of immunogenic determinants, which are confined to a few loci on the polypeptide molecule, (see Crumpton, M.J., in The Antigens (ed. Sela, M., Academic Press, New York, 1974); Benjamini, E. et al. , Curr. Topics Microbiol. Immunol. 58, 85-135 (1972); and Atassi, M.Z., Immunochemistry 12, 423-438 (1975).) Antisera prepared against chemically synthesized peptides corresponding to short linear stretches of the polypeptide sequence have been shown to react well with the whole polypeptide, (see Green, N. et al., Cell 28, 477-487 (1982); Bittle, J.L. et al.. Nature 298, 30-33 (1982); Dreesman et al.,
Nature 295, 158-160 (1982); Prince, A.M., Ikram, H., Hopp, T.P., Proc. Nat. Acad.Sci. USA 79, 579-582 (1982); Lerner, R.A. et al., Proc.Nat.Acad.Sci.USA 78, 3403-3407 (1981); and Neurath, A.R., Kent, S.B.H., Strick, N., Proc.Nat.Acad.Sci. USA 79,
7871-7875 (1982).) However, interactions have been found to occur even when the site of interaction does not correlate with the immunogenic determinants of the native protein, (see Green, N., et al. Supra). Conversely, since antibodies produced against the native protein are by definition directed to the immunogenic determinants, it follows that a peptide interacting with these antibodies must contain at least a part of an immunogenic determinant.
From a study of the few proteins for which the immunogenic determinants have been accurately mapped, it is clear that a determinant can consist of a single sequence, (continuous), or of several sequences (discontinuous) brought together from linearly distant regions of the polypeptide chain by the folding of that chain as it exists in the native state, (see Atassi, M.Z., Immunochemistry 15, 909-936 (1978).). As in the case of lysozyme several of the elements consist of only one amino acid, the size of a contributing element can then vary between one and the maximum number of amino acids consistent with the dimensions of the antibody combining site, and is likely to be of the order of five to six, (see Atassi, M.Z., supra). Any systematic mapping of all the detectable antigenic elements of a polypeptide by the chemical synthesis of overlapping segments and measurement of their subsequent reactivity with antisera prepared against the native protein has until now been severely limited by the scale of the synthetic and testing capability required, (see
Atassi, M.Z., supra, and Kazim, A.L., Atassi, M.Z., Biochem.J. 191, 261-264 (1980)).
The precise localisation of immunogenic determinants within the amino acid sequence of a few proteins has been performed by one or more of the following approaches: (1) antigenicity measurements of the whole polypeptide or peptide fragments isolated therefrom, before and after chemical modification at specific residues; (2) locating the position, within the polypeptide amino acid sequence of substitutions, selected by growing the virus expressing the protein in the presence of monoclonal antibodies; and (3) synthesis and testing of peptides, homologous with the amino acid sequence, of regions suspected of immunogenic activity. This last method probably gives the best opportunities for a comprehensive approach; however, the synthesis and purification of numerous peptides requires a great deal of expertise and time. Smith, J.A., et al, Immunochemistry 14, 565-568
(1977), circumvented the decoupling and purification steps by combining solid-phase peptide synthesis and solid-phase radio-immune assay using the same solid support, (see also Hurrell, J.G.R., Smith, J.A., Leach, S.J., Immunochemistry 15, 297-302 (1978)). With this procedure they were able to confirm the locations of the continuous immunogenic determinants of two proteins. However, even with this simplified approach, any systematic scan for antibody-binding activity of all possible hexapeptides from even a relatively small protein such as Virus Protein 1 (VP1) of foot-and-mouth disease virus (FMDV) which is known to have 213 amino acids, would take an unacceptably long time.
The FMD virus, which belongs to the aphthovirus genus of the family Picornaviridae, consists of an ordered aggregation of structurally independent sub-units surrounding a molecule of infectious single-stranded RNA. Under relatively mild conditions the whole particle readily dis-aggregates to give the naked RNA, 60 copies of the VP4 polypeptide, and 12 sub-units consisting of an ordered arrangement of five copies of each of the polypeptides, VP1, VP2 and VP3. Each of these structural sub-units can be further disrupted to yield the isolated component proteins. The VP1 protein of FMD virus has been shown to be an immunologically important coat protein of the virus.
Following the development of new techniques for the solid-phase synthesis of peptides, it has now become possible to develop a method for the concurrent synthesis on solid supports of hundreds of peptides. Interaction of synthesized peptides with antibodies is then easily detected without removing them from the support. A preferred method for solid-phase synthesis according to the present invention comprises the use of a polymeric material such as polyethylene or polypropylene as the solid-phase carrier, onto which is graft polymerised a vinyl monomer containing at least one functional group to produce polymeric chains on the carrier. The functional groups of these polymeric chains are then reacted to provide primary or secondary amino groups of the chains, and these amino groups are then sequentially reacted with amino acid residues in appropriate order so as to build up a desired synthetic peptide. The carrier is preferably in the form of a solid polymer rod having a diameter of about 4mm and a length of about 50mm. A number of such rods can be held in a suitable holder in a 12 x 8 grid whose dimensions correspond to those of the standard microtitre plate used for enzyme-linked immunosorbent assays (ELISA).
As a result of work now carried out using the above technique, peptides which constitute immunogenic determinant (s) of the VP1 coat proteins of a number of important serotypes of foot-and-mouth disease virus have been identified and chemically synthesized. Note : Throughout this specification amino acid residues will be denoted by the three-letter abbreviation or single-letter code as follows : -
Figure imgf000009_0001
In broad terms, the present invention provides a synthetic peptide which displays the antigenicity of the VP1 protein of foot-and-mouth disease virus, characterised in that at least a portion of said peptide is selected from the group consisting of five-, six- or seven-long antigenically active amino acid sequences of said VP1 protein, and antigenically active modified sequences (as hereinafter defined) thereof.
According to a first aspect of the present invention, there is provided a synthetic peptide which displays the antigenicity of the VP1 protein of foot-and-mouth disease virus, Type O1, characterised in that at least a portion of said peptide is selected from amino acid sequences of the group consisting of:
(i) G - D - L - Q - V - L - A; (ii) G - D - L - Q - V - L; (iii) D - L - Q - V - L - A; (iv) D - L - Q - V - L; and
(v) antigenically active modified sequences (as hereinafter defined) based on any one of the sequences (i) to (iv) above.
According to a second aspect of the present invention, there is provided a synthetic peptide which displays the antigenicity of the VP1 protein of foot-and-mouth disease virus, type A10 (A61), characterised in that at least a portion of said peptide is selected from amino acid sequences of the group consisting of:
(i) G - D - L - G - S - I - A; (ii) G - D - L - G - S - I;
(iii) D - L - G - S - I - A;
(iv) D - L - G - S - I; and
(v) antigenically active modified sequences (as hereinafter defined) based on any one of the sequences (i) to (iv) above.
According to a third aspect of the present invention, there is provided a synthetic peptide which displays the antigenicity of the VP1 protein of foot-and-mouth disease virus, type C1, characterised in that at least a portion of said peptide is selected from amino acid sequences of the group consisting of:
(i) D - L - A - H - L - T - A; (ii) D - L - A - H - L - T; (iii) L - A - H - L - T - A; (iv) L - A - H - L - T; and
(v) antigenically active modified sequences (as hereinafter defined) based on any one of the sequences (i) to (iv) above.
The term "antigenically active modified sequences" as used herein, is used to describe sequences of amino acids which are based on any one of sequences (i) to (iv) of the first, second or third aspects of the invention as described above, but in which one of the amino acids in the said sequence is replaced by another amino acid to provide a modified sequence which is antigenically active.
Antigenically active modified sequences in accordance with the first aspect of this invention include hexapeptide sequences based on the formula:
G - D - L - Q - V - L (1) (2) (3) (4) (5) (6)
in which:
G at position (1) is replaced by A, H, I, K, M,
N, P, Q, S or T; or D at position (2) is replaced by A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V or Y; or
Q at position (4) is replaced by D, K, A, M, E,
N, S or R; or V at position (5) is replaced by A, D, E, F, I, K, L, M, N, Q, R, S, T or Y.
Antigenically active modified sequences in accordance with the second aspect of this invention include hexapeptide sequences based on the formula:
G - D - L - G - S - I
(1) (2) (3) (4) (5) (6)
in which:
G at position (1) is replaced by A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; or D at position (2) is replaced by L; or
G at position (4) is replaced by A; or
S at position (5) is replaced by T, G or A; or
I at position (6) is replaced by A, C, D, E, F, K, L, M, Q, R, S, T, V, W or Y.
Antigenically active modified sequences in accordance with the third aspect of this invention include hexapeptide sequences based on the formula:
D - L - A - H - L - T (1) (2) (3) (4) (5) (6)
in which: D at position (1) is replaced by H or V; or
H at position (4) is replaced by A, C, D, E, F,
K, L, M, N, Q, R, S, T, V or Y; or T at position (6) is replaced by S.
In arriving at this invention, the concurrent chemical synthesis of all possible hexapeptides representing the total sequences of the VP1 coat proteins of FMD virus, types O1, A10 (or A61) and C1, with the overlap of five amino acids between peptides in juxtaposition in the sequence has been completed using the solid-phase synthesis technique described above. The synthetic peptides, still attached to the support used for their synthesis, have been tested for antibody-binding activity by ELISA to produce a complete map of all the reactive sequences of the VP1 proteins at a resolution of six amino acids. A peptide length of six amino acids was chosen, taking into account the following factors:
1. antibody interactions with hexapeptides have been demonstrated; 2. the longer a peptide the greater the possibility of its folding with a secondary structure, this folding not necessarily being that occurring in the native protein;
3. during synthesis the yield of the desired peptide decreases as the number of coupling reactions increases; and
4. the smaller the sequence synthesized the greater the precision in specifying the bounds of a detected active sequence within the whole sequence.
As set out above, the peptides of the present invention are characterised in that at least a portion of the peptide contains an amino acid sequence selected from the groups (i) to (v) described above. Tests which have been carried out, particularly utilising the ELISA technique, have established the activity of these amino acid sequences by their reactivity with antisera. It should be noted, however, that whilst the synthetic peptides of this invention may comprise sequences which are only 5, 6 or 7 amino acids long, the present invention also extends to synthetic peptides in which one or more additional amino acids are included on either or both ends of the defined sequence, that is either on the carboxyl (-COOH) end or on the amino (-NH2) end or both. While such additional amino acids may not play any direct role in enhancing the immunogenic activity of the defined amino acid sequence, they may act, for example, as spacer amino acids to space the antigenically active amino acid sequence from the free carboxyl and/or free amino ends of the sequence.
Following identification of the antigenically active amino acid sequences of the VP1 proteins, the modified sequences in accordance with this invention have been similarly synthesised and tested utilising the ELISA technique. As previously described, each of these modified sequences was derived by replacing one amino acid in the original sequence by another amino acid.
The peptides of the present invention can be chemically synthesized from their constituent amino acids. This synthesis may be carried out, for example, by the Merrifield solid-phase method, as described in J.A.C.S. 85: 2149-2154 (1963). In the Merrifield solid-phase method, the C-terminal amino acid is attached to chloromethylated polystyrene-divinylbenzene copolymer beads. Each subsequent amino acid, with a suitable protecting group if necessary, is then added sequentially to the growing chain. As described in the Merrifield article, the protective group may be, for example, a t-butyloxycarbonyl or carbobenzoxy group. By the procedure of coupling, deprotection, and coupling of the next amino acid, the desired amino acid sequence and chain length can be produced. As a final step, the protective group is removed from N-terminal amino acid, and the C-terminal amino acid is cleaved from the supporting beads, using a suitable reagent such as trifluoroacetic acid and hydrogen bromide.
Alternatively, the synthesis can be carried out by the solid-phase method, in which the synthetic peptide structure is built up on a solid-phase carrier which comprises a polymeric material, for example a polyethylene rod or pin, having a vinyl monomer graft polymerised thereto, for example by γ-radiation of acrylic acid, acrylonitrile or acrylamide monomers. A mono- protected biamine such as lysine or lysine-alanine is then reacted with the polymeric chain formed on the solid-phase carrier and the synthetic peptide then built up by sequential reaction of amino acids in the same manner as in the Merrifield method described above.
It should be noted that whilst the final step in both the methods referred to above is the removal of the synthetic peptide from the solid-phase carrier or support by a cleaving reaction using a suitable reagent, for some uses of the peptides of the present invention it is convenient if not essential for the chemically synthesized peptides to be used in the form of a product in which the peptide is coupled or linked to a solid-phase carrier or support. For such uses, of course, the final cleaving step is omitted. Such antigenically active, chemically synthesized peptides which are immobilised on a solid-phase carrier or support are of particular utility in the performance of immunochemical assays, such as enzyme immunoassays (EIA).
The immunogenic synthetic peptides of the present invention may provide the basis upon which the formation of synthetic vaccines against foot-and-mouth disease virus can be developed. Such synthetic vaccines would have particular merit insofar as they could be manufactured so as to be free of amino acid sequences corresponding to the entire amino acid sequences of the viral protein, and also free of biologically produced materials and of active or inactivated viral residues. The use of synthetic peptides as the basis for vaccines is discussed, for example, by Beale, J. in Nature 298 14-15 (1982), and by Sutcliffe, J.G. et al in Science, 219, 660-666 (1982). In formation of a synthetic vaccine, the synthetic peptides of the present invention could be used either alone, in combination, and/or in association with a physiologically acceptable carrier and/or adjuvant. The synthetic peptides of the present invention also have potential for use in a number of other applications in the immunological field, including use in diagnostic and other immunological testing procedures, particularly in immunochemical assays such as enzyme immunoassays.
Further details of the peptide compounds of this invention, their method of preparation and their antigenic activity are illustrated by the following Examples:
EXAMPLE 1.
A. Preparation of hexapeptides.
The 213-amino acid sequence of VP1 (FMDV, type O1) as translated by Kurz, C. et al., Nucleic Acid Research 9 , 1919-1931 (1981) was subdivided into all possible hexapeptide units, and each hexapeptide unit was synthesized on a polyethylene support in the same orientation, and with a 2-long amino acid spacer as illustrated in Figure 1.
Polyethylene rods immersed in a 6% v/v aqueous solution of acrylic acid were γ-ray irradiated at a dose of 1 Mrad (see Muller-Schulte, D., Horster, F.A., Polymer Bulletin 7 , 77-81 (1982)). Using conventional methods of solid-phase peptide chemistry (see
Erickson, B.W., Merrifield, R.B. in "The Proteins", Vol.2, 255-257, Academic Press, New York (1976); Meienhofer, J., in "Hormonal Proteins and Peptides", Vol.2. 45-267, Academic Press, New York (1973)), Nα-t-Butyloxycarbonyl-L-Lysine methyl ester was coupled to the polyethylene polyacrylic acid (PPA) via the N -amino group of the side-chain. This was followed by the coupling of Boc-Alanine, to complete a peptide-like spacer. Amino-substitution of the support was determined by reacting NH2-Lysine(OMe)-PPA with C14 labelled butyric acid, and was found to be 8-10 nmoles/rod.
Successive amino acids were added by conventional solid phase peptide synthesis as dictated by the sequence to be synthesized. At the completion of the final coupling reaction, and after removal of the t-butyloxycarbonyl (Boc) protecting group, the terminal amino group was acetylated with acetic anhydride in a dimethylformamide (DMF) /triethylamine mixture. All dicyclohexyl carbodiimide-mediated coupling reactions were carried out in DMF in the presence of N-hydroxy benzotriazole. The following side-chain protecting groups were used; O-benzyl for threonine, serine, aspartic acid, glutamic acid and tyrosine; carbobenzoxy for lysine; tosyl for arginine; 4-methyl benzyl for cysteine and 1-benzyloxycarbonylamido-2,2,2,-trifluoroethyl for histidine. Side-chain deprotection was achieved by treatment with borontris (trifluoracetate) in trifluoroacetic acid for 90 minutes at room temperature (see Pless, J., Bauer, W., Angewante Chemie 85, 142 (1973)). After hydrolysis in HCl/propionic acid, analysis of sequences included in the synthesis as controls confirmed that coupling at each stage had occurred. Before testing by ELISA, rod-coupled peptides were washed several times in phosphate buffered saline (PBS).
B. Testing of Hexapeptides. Antigenic profiles for the hexapeptides prepared as described in A. above are shown in Figure 2 as a vertical line proportional to the ELISA extinction obtained, over the number giving the location within the VP1 sequence of the peptide N-terminal amino acid. Antisera used to produce the different profiles as shown, were as follows: (a) and (b) two different anti-intact virus particle, type O1; (c) anti-intact virus particle, as used in (b), after absorption with purified complete virus, type O1;
(d) anti-virus-subunit, type O1;
(e) anti-VP1, type O1 and
(f) anti-intact virus particle, type C1.
The enzyme-linked immunosorbent assay was used to test each rod-coupled peptide (RCP) for reactivity with each of the defined antisera described above. RCPs were pre-coated with 10% horse serum, 10% ovalbumin and 1% Tween-80 in PBS, to block non-specific absorption of antibodies, for 1 hour at 37°C. Overnight incubation at 4°C in antiserum diluted 1/40 in the preincubation mixture, was followed by 3 washes in 0.05% Tween-80/PBS. Reaction for 1 hour at 37°C with the appropriate anti-rabbit
IgG immunoglobulin coupled to horse radish peroxidase, diluted 1/50,000 in the preincubation mixture, was again followed by extensive washing in PBS/Tween to remove excess conjugate. The presence of antibody was detected by reaction for 45 min with a developing solution (40 mg orthophenylenediamine, 20 μl of hydrogen peroxide in 100 ml of phosphate buffer, pH 5.0), and the colour produced read in a Titertek Multiscan at 420 nm. After tests, peptides were washed three times at 37°C in 8M urea containing 0.1% 2-mercaptoethanol and 0.1% sodium dodecyl sulphate, followed by several washes in PBS to remove all traces of bound antibody. The RCPs were then ready for further testing with different antisera.
Anti-intact virus particle sera were prepared by immunising rabbits with 50 μg of inactivated, purified virus in complete Freund's adjuvant. The animals were bled 3-4 weeks after the single vaccination. Anti-virus-subunit serum (rabbit) was prepared by immunizing 3 times, 3-4 weeks apart, with 10 μg of acid-disrupted purified virus, initially in complete Freund's and subsequently in incomplete Freund's adjuvant. The polypeptide VP1 was separated from the mixture of proteins obtained from urea disrupted, purified virus, by iso-electric focusing. (see
Barteling, S.J., Wagenaar, F., Gielkens, A.L.J., J.Gen.Virol. 62, 357-361 (1982).) After elution from the gel with 8M urea and dialysis against PBS, antiserum was raised as described for 12S above. Antiserum for scan (c) was that used for scan (b), but after absorption with purified virus (1500 μg complete virus was incubated with 1 ml of serum for 72 hours at 4°C), and all virus bound antibodies removed by centrifugation. C. Identification of the virus particle-associated antigenic peptide.
Of the four anti-intact virus particle sera tested, scans (a) and (b) show the extremes in the reactivity patterns found. Large quantitative differences in the response to an identical antigen preparation have been reported before, however, these scans highlight the variability possible in the antibody composition between sera. From an examination of scans (a), (b) and (c), antibody reactive with peptides numbers 146 and 147 are present in whole anti-intact virus sera, but absent after absorption with purified virus. These same antibodies are not observed in the anti-subunit sera, scan (d), and only weakly present in the anti-VP1 sera, scan (e). That some activity was found in the anti-VP1 sera, possibly accounts for the immunizing capacity, albeit weak, of the isolated protein, (see Kleid, D.G., et al., Science 214, 1125-1129 (1981).) It should be noted however that another anti-VP1 serum also tested, while retaining a strong activity in position number 148, showed nothing at positions numbers 146 and 147. The superimposition of scan (c) on scan (b) (absorbed compared to non-absorbed) shows that in addition to the loss of activity to peptides numbers 146 and 147, a reduction in activity to peptides numbers 5, 6 and 206 also occurred. Of these, activity to numbers 5 and 6 was not found in all the anti-intact virus sera tested, whilst number 206 activity was invariably present. From these results, it is concluded that of the sequences found to be reactive, the pair at numbers 146 and 147, that is the hexapeptides Gly-Asp-Leu-Gln-Val-Leu (G - D - L - Q - V - L) and Asp-Leu-Gln-Val-Leu-Ala (D - L - Q - V - L -A), constitute the principal loci, with a lesser contribution from the locus at number 206, consistent with the observations of others. However, with respect to the loci at numbers 146-7, we do not distinguish between the two possibilities; one, that the active element is five amino acids long, i.e. the sequence common to both Asp-Leu-Gln-Val-Leu (D - L Q - V - L); or two, that the active element is seven amino acids long, i.e. the combination of the two hexapeptides Gly-Asp-Leu-Gln-Val-Leu-Ala (G - D - L Q - V - L - A).
EXAMPLE 2
Preparation of hexapeptides.
The 212 amino acid sequence of VP1 (FMDV type A10 or A61) as given by Bachrach, H.L., et al. Office International des, Epizootics was subdivided into 207 hexapeptides. These hexapeptides were synthesised as described in Example 1 above with the exception that the side chain of arginine was protected by the p-methoxybenzene sulphonyl group.
B. Testing of hexapeptides. Antigenic profiles for the hexapeptides are shown in Figure 3. The antisera used to produce the profiles were:¬
(a) anti-intact virus particle type A10
(b) anti-intact virus particle as used in (a) after adsorption with purified complete FMDV type
A10.
The testing of the hexapeptide and preparation of the sera were essentially as described in Example 1.
C. Identification of virus-particle associated active element.
By reasoning identical to that used in Example 1 it is concluded that the hexapeptides
Gly-Asp-Leu-Gly-Ser-Ile (G - D - L - G - S - I) and Asp-Leu-Gly-Ser-Ile-Ala (D - L - G - S - I - A) are the principal loci for the antigenic determinant of the A-type of FMDV.
As in the case of FMD virus, type O1, described in Example 1, we did not distinguish between these two sequences, and accordingly it is concluded that it is possible that the active sequence is five amino acids long, i.e. Asp-Leu-Gly-Ser-Ile (D - L ¬
G - S - I), or that it is seven amino acids long, i.e. Gly-Asp-Leu-Gly-Ser-Ile-Ala (G - D - L - G - S - I A). EXAMPLE 3.
A. Preparation of hexapeptides.
The 210 amino acid sequence of VP1 (FMDV type C1) as given by Robertson, H.L., et al., Journal of Virology, 46, 311-316 (1983) was subdivided into 205 hexapeptides. These hexapeptides were synthesised as described in Example 2 above.
B. Testing of hexapeptides.
Antigenic profiles for the hexapeptides are shown in Figure 4. The antisera used to produce the profiles were:¬
(a) anti-intact virus particle type C1
(b) anti-intact virus particle as used in (a) after absorption with purified complete FMDV type
The testing of the hexapeptide and preparation of the sera were essentially as described in Example 1.
C. Identification of virus-particle associated active element.
By reasoning identical to that used in Example 1 it is concluded that the hexapeptide Asp-Leu-Ala-HisLeu-Thr (D - L - A - H - L - T) is the principal locus for the antigenic determinant of the C-type of FMDV. These results clearly show the potential of a systematic scanning of a polypeptide sequence. They point out the likely location of the active determinant encompassed within the peptide with which Bittle, J.L. et al. Nature 298, 30-33 (1982), obtained the successful protection in guinea pigs to a subsequent challenge by FMDV.
EXAMPLE 4
A. Preparation of Peptides containing Replacement Amino Acids.
The synthesis method of Example 1 was used to synthesize 120 hexapeptides, each consisting of five original amino acids of the antigenic hexapeptide G D - L - Q - V- L (type O1), the other amino acid being systematically replaced with each of the 20 possible naturally occurring genetically coded amino acids. This replacement was performed at each of the six positions in the peptide in turn. Thus, the 120 peptides comprised six copies of the original sequence and 114 variations of the original sequence, each of the 114 variations differing in only one amino acid from the original sequence. This strategy is illustrated diagrammatically in Fig.5.
B. Testing of Peptides containing Replacement Amino Acids. The ELISA test of Example 1 was used to test the 120 peptides against an antiserum known to react with the original sequence. The results are shown in Fig.6 and Table 1. In Fig.6, the antibody-binding activity for each peptide is shown as a vertical line proportional to the ELISA extinction obtained. Within a group of 20 lines the left-hand line corresponds to the substitution of the original residue by alanine (A), and the right-hand line is for the substitution by tyrosine (Y). Lines in between are in alphabetic order according to the single letter code for each amino acid. Every group of twenty lines corresponds to the complete replacement set for one of the six N-terminal residue positions in the hexapeptide G D - L - Q - V - L. It can be seen that the amino acids at certain positions in the sequence can be readily replaced without loss of antigenicity, whereas other positions cannot accept replacement without partial or complete loss of antigenicity. Those peptides containing replacements which result in retained antigenicity are candidates for use in vaccine manufacture.
C. The preparation and testing methods of A. and B. above were repeated with the antigenic hexapeptides G - D - L - G - S - I (type A10) and D - L - A - H L - T (type C1) - see Fig.5. The results are shown in Table 1. EXAMPLE 5.
The selected antigenic peptides of each of the three FMDV types were synthesized with a variety of linking amino acids at the N-terminal end and with the linking amino acid lysine at the C-terminal end. The amino acids in the links do not occur in those positions in the native sequences. The synthesized peptides were coupled to a protein carrier and combined with an adjuvant for the purpose of animal immunisation. The carrier was keyhole limpet hemocyanin (KLH) and the adjuvant was either an oil adjuvant or aluminium hydroxide gel.
Table 2 gives the results of serological tests on immunised rabbits. It shows that in each case the rabbit produced a significant amount of antibody able to react with FMDV and able to neutralise the infectivity of FMDV.
EXAMPLE 6.
A protection test was carried out using guinea pigs as a model, since guinea pigs are susceptible to infection with FMDV. The peptide used for immunisation was C - G - D - L - Q - V - L - A - K, which is made up of the heptapeptide G - D - L - Q V - L - A from FMDV type O1 (residues 146-152), a cysteine linker at the N-terminal end and a lysine linker at the C-terminal end. To prepare the vaccine, the peptide was coupled to KLH using maleimidobenzoyl N-hydroxysuccinimide ester, which links the peptide to the KLH via the cysteine side chain.
The KLH-peptide conjugate was then absorbed to an aluminium hydroxide gel and used to vaccinate the guinea pigs at a dose of 100μg peptide per animal. An unvaccinated group of guinea pigs served as controls. The animals were challenged 21 days after the single vaccination.
Figure imgf000029_0001
These results show that the short peptide sequence used can stimulate the immune system of a model susceptible animal to give a protective response against challenge by virulent FMDV. EXAMPLE 7 .
An example of the application of the present invention for diagnostic use is drawn from Fig.2. This shows that ELISA testing using support-coupled peptides (SCPs) is an extremely strain-specific tool for detecting FMDV antibodies. Whole antisera to FMDV type O1 reacted with hexapeptides 146, 147 and 206 derived from the FMDV type O1 sequence, whereas antiserum to type C1 did not react at all. Control testing on the antiserum to FMDV type C1 showed that, likewise, specific reaction only occurred with peptides derived from the C1 sequence. Testing of the SCPs with other non-FMDV-specific control sera, and hyperimmune sera to other FMDV types, has also shown that no reaction occurs.
Animal sera can therefore be tested on selected FMDV SCPs and a positive reaction is diagnostic of a previous exposure of the animal to FMDV antigen.
Figure imgf000031_0001
Figure imgf000032_0001
It will, of course, be recognised that many variations and modifications may be made to the detailed description of the method of the present invention given above without departing from the method of the invention as broadly described herein.

Claims

CLAIMS:
1. A synthetic peptide which displays the antigenicity of the VP1 protein of foot-and-mouth disease virus, characterised in that at least a portion of said peptide is selected from the group consisting of five-, six- or seven-long antigenically active amino acid sequences of said VP1 protein, and antigenically active modified sequences thereof.
2. A synthetic peptide which displays the antigenicity of the VP1 protein of foot-and-mouth disease virus, Type O1, characterised in that at least a portion of said peptide is selected from amino acid sequences of the group consisting of:
(i) G - D - L - Q - V - L - A;
(ii) G - D - L - Q - V - L;
(iii) D - L - Q - V - L - A;
(iv) D - L - Q - V - L; and
(v) antigenically active modified sequences (as herein defined) based on any one of the sequences (i) to (iv) above.
3. A synthetic peptide which displays the antigenicity of the VP1 protein of foot-and-mouth disease virus, type A10 (A61), characterised in that at least a portion of said peptide is selected from amino acid sequences of the group consisting of:
(i) G - D - L - G - S - I - A; (ii) G - D - L - G - S - I;
(iii) D - L - G - S - I - A;
(iv) D - L - G - S - I; and
(v) antigenically active modified sequences (as herein defined) based on any one of the sequences (i) to (iv) above.
4. A synthetic peptide which displays the antigenicity of the VP1 protein of foot-and-mouth disease virus, type C1, characterised in that at least a portion of said peptide is selected from amino acid sequences of the group consisting of:
(i) D - L - A - H - L - T - A;
(ii) D - L - A - H - L - T;
(iii) L - A - H - L - T - A;
(iv) L - A - H - L - T; and
(v) antigenically active modified sequences (as herein defined) based on any one of the sequences (i) to (iv) above.
5. A synthetic peptide according to claim 2, characterised in that at least a portion thereof is selected from hexapeptide sequences based on the formula:
G - D - L - Q - V - L (1) (2) (3) (4). (5) (6)
in which:
G at position (1) is replaced by A, H, I, K, M, N, P, Q, S or T; or D at position (2) is replaced by A, C, E, F, G,
H, I, K, L, M, N, P, Q, R, S, T, V or Y; or Q at position (4) is replaced by D, K, A, M, E,
N, S or R; or V at position (5) is replaced by A, D, E, F, I,
K, L, M, N, Q, R, S, T or Y.
6. A synthetic peptide according to claim 3, characterised in that at least a portion thereof is selected from hexapeptide sequences based on the formula:
G - D - L - G - S - I (1) (2) (3) (4) (5) (6)
in which:
G at position (1) is replaced by A, C, D, E, F,
H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; or D at position (2) is replaced by L; or G at position (4) is replaced by A; or S at position (5) is replaced by T, G or A; or I at position (6) is replaced by A, C, D, E, F,
K, L, M, Q, R, S, T, V, W or Y.
7. A synthetic peptide according to claim 4, characterised in that at least a portion thereof is selected from hexapeptide sequences based on the formula: D - L - A - H - L - T (1) (2) (3) (4) (5) (6)
in which:
D at position (1) is replaced by H or V; or H at position (4) is replaced by A, C, D, E, F,
K, L, M, N, Q, R, S, T, V or Y; or T at position (6) is replaced by S.
8. A vaccine for treating animals against infection by foot-and-mouth disease virus, comprising at least one synthetic peptide according to any one of claims 1 to 7.
9. A vaccine according to claim 8, further comprising a physiologically acceptable carrier and/or adjuvant.
10. A vaccine according to claim 8 or 9, wherein said at least one synthetic peptide is linked to said physiologically acceptable carrier.
11. A method of treating animals against infection by foot-and-mouth disease virus, which comprises administering to the said animals a vaccine according to any one of claims 8 to 10.
12. A diagnostic or other immunological testing system for detecting the presence of foot-and-mouth disease virus or of antibodies against foot-and-mouth disease virus in an animal, characterised in that it comprises at least one synthetic peptide according to any one of claims 1 to 7 as an antigenically active component of said system.
PCT/AU1984/000038 1983-03-08 1984-03-08 Antigenically active amino acid sequences WO1984003506A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
DE8484900954T DE3485972T2 (en) 1983-03-08 1984-03-08 ANTIG ACTIVE AMINO ACID SEQUENCES.
AT84900954T ATE82018T1 (en) 1983-03-08 1984-03-08 ANTIGEN ACTIVE AMINO ACID SEQUENCES.
NO844295A NO167745C (en) 1983-03-08 1984-10-29 ANALOGY PROCEDURE FOR THE PREPARATION OF TERPEUTIC ACTIVE SYNTHETIC PEPTIDES.
DK532184A DK171118B1 (en) 1983-03-08 1984-11-08 Synthetic peptide which exhibits the antigenicity which is characteristic of the VP1 protein from the foot and mouth disease virus, and a vaccine and a diagnostic test system which comprise it

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPF834783 1983-03-08
AU25428/84A AU573574B2 (en) 1983-03-08 1984-03-08 Immunogenic deteminants of foot and mouth disease virus

Publications (1)

Publication Number Publication Date
WO1984003506A1 true WO1984003506A1 (en) 1984-09-13

Family

ID=25619678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1984/000038 WO1984003506A1 (en) 1983-03-08 1984-03-08 Antigenically active amino acid sequences

Country Status (1)

Country Link
WO (1) WO1984003506A1 (en)

Cited By (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114759A2 (en) * 1983-01-24 1984-08-01 Bruce Heywood Nicholson Amino acid sequences and polypeptides including these sequences and having the specificity of foot and mouth disease and other viral antigens
EP0138855A1 (en) * 1983-03-08 1985-05-02 Commw Serum Lab Commission Method of determining antigenically active amino acid sequences.
EP0180564A2 (en) * 1984-11-01 1986-05-07 Bror Morein Immunogenic complex, a method for producing the same, and the use thereof as an immune stimulant, vaccines and reagents
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
WO1986006487A1 (en) 1985-04-22 1986-11-06 Commonwealth Serum Laboratories Commission Method for determining mimotopes
FR2591227A1 (en) * 1985-12-06 1987-06-12 Pasteur Institut PEPTIDES CAPABLE OF INHIBITING INTERACTIONS BETWEEN LAV VIRUSES AND T4 LYMPHOCYTES, PRODUCTS DERIVED THEREFROM, AND APPLICATIONS THEREOF
FR2600335A1 (en) * 1986-06-19 1987-12-24 Pasteur Institut METHOD OF ANALYZING IMMUNOGENIC PEPTIDE SEQUENCES CARRYING A CHARACTERISTIC EPITOPE OF A FOREIGN PROTEIN WITH THE ORGANISM OF A LIVING HOST, FOR VACCINE PRODUCTION
FR2631451A1 (en) * 1988-05-13 1989-11-17 Inst Nat Sante Rech Med Locating epitope(s) in protein reactive with monoclonal antibodies - by testing immuno-reactivity of truncated polypeptide(s) translated from fragments of C-DNA
US5063150A (en) * 1984-09-19 1991-11-05 The Regents Of The University Of California Retroviral polypeptides associated with human cellular transformation
WO1993018054A2 (en) * 1992-03-06 1993-09-16 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US5286789A (en) * 1989-05-26 1994-02-15 Applied Immune Sciences, Inc. Solid phase multiple peptide synthesis
US5504190A (en) * 1990-11-21 1996-04-02 Torrey Pines Institute For Molecular Studies Equimolar multiple oligomer mixtures, especially oligopeptide mixtures
US5582997A (en) * 1994-08-24 1996-12-10 Torrey Pines Institute For Molecular Studies Lysine/leucine polypeptides, mixture sets and libraries thereof
US5593679A (en) * 1987-10-26 1997-01-14 Akzo Nobel N.V. Poultry vaccine against E. coli air sac inflammation and septicaemia
US5645996A (en) * 1994-08-24 1997-07-08 Torrey Pines Institute For Molecular Studies Melittin-related polypeptides, mixture sets and libraries thereof
US5763193A (en) * 1993-06-17 1998-06-09 Torrey Pines Institute For Molecular Studies Peralkylated oligopeptide mixtures
US5846731A (en) * 1993-06-17 1998-12-08 Torry Pines Institute For Molecular Studies Peralkylated oligopeptide mixtures
US5866363A (en) * 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
US6197529B1 (en) 1990-11-21 2001-03-06 Torrey Pines Institute For Molecular Studies Linear substituted oligoalkyleneimine libraries
US6287787B1 (en) 1993-11-24 2001-09-11 Torrey Pines Institute For Molecular Studies Dimeric oligopeptide mixture sets
US6579682B1 (en) 1998-03-10 2003-06-17 The Regents Of University Of California Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding
WO2003066672A1 (en) * 2002-02-08 2003-08-14 Nakoshi, Hideo Peptides
US6649735B1 (en) 1992-03-06 2003-11-18 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
WO2007126439A2 (en) 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
WO2008067223A2 (en) 2006-11-29 2008-06-05 Genentech, Inc. Il-17a/f heterodimeric polypeptides and therapeutic uses thereof
WO2008103962A2 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
EP1992643A2 (en) 2001-06-20 2008-11-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1995321A2 (en) 2005-08-15 2008-11-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP2002714A1 (en) 2005-11-21 2008-12-17 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP2011886A2 (en) 2002-04-16 2009-01-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2050763A2 (en) 2005-03-10 2009-04-22 Genentech, Inc. Methods and compositions for modulating vascular integrity
EP2050335A1 (en) 2006-02-17 2009-04-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP2067472A1 (en) 2002-01-02 2009-06-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP2083018A2 (en) 2003-04-16 2009-07-29 Genentech, Inc. Compositions and methods relating to STOP-1
EP2143438A1 (en) 2001-09-18 2010-01-13 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2161283A1 (en) 2003-11-17 2010-03-10 Genentech, Inc. Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or cytotoxic agent and methods for the treatment of tumor of hematopoietic origin
EP2186402A1 (en) 2005-06-06 2010-05-19 Genentech, Inc. Knock-out animal models for novel genes and methods of use
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2277908A2 (en) 2003-07-08 2011-01-26 Genentech, Inc. IL-17A/F heterologous polypeptides, antibodies and therapeutic uses thereof
WO2011026200A2 (en) 2009-09-02 2011-03-10 Katholieke Universiteit Leuven New methods for diagnosing autoimmune diseases
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
WO2011050194A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011066503A2 (en) 2009-11-30 2011-06-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2011103242A1 (en) 2010-02-18 2011-08-25 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011106297A2 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2011139985A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2386655A2 (en) 2006-09-12 2011-11-16 Genentech, Inc. Methods and compositions for the diagnosis and treatment of lung cancer using KIT or KDG gene as genetic marker
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
US8309351B2 (en) 2007-10-04 2012-11-13 Bionomics Limited Methods of identifying agents that inhibit angiogenesis
WO2013019906A1 (en) 2011-08-01 2013-02-07 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
WO2013040433A1 (en) 2011-09-15 2013-03-21 Genentech, Inc. Methods of promoting differentiation
WO2013056148A2 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
EP2614839A2 (en) 2006-04-05 2013-07-17 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
WO2013109856A2 (en) 2012-01-18 2013-07-25 Genentech, Inc. Methods of using fgf19 modulators
WO2013120056A1 (en) 2012-02-11 2013-08-15 Genentech, Inc. R-spondin translocations and methods using the same
WO2013137920A1 (en) 2012-03-16 2013-09-19 Genentech, Inc. Engineered conformationally-stabilized proteins
WO2013135745A1 (en) 2012-03-16 2013-09-19 F. Hoffmann-La Roche Ag Methods of treating melanoma with pak1 inhibitors
WO2013162654A1 (en) 2012-04-25 2013-10-31 Biodesy, Llc Methods for detecting allosteric modulators of proteins
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
WO2013181452A1 (en) 2012-05-31 2013-12-05 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
WO2014138364A2 (en) 2013-03-06 2014-09-12 Genentech, Inc. Methods of treating and preventing cancer drug resistance
WO2014144850A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
WO2014145016A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
WO2014151006A2 (en) 2013-03-15 2014-09-25 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
WO2014153030A2 (en) 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
WO2014205344A2 (en) 2013-06-21 2014-12-24 The Johns Hopkins University Virion display array for profiling functions and interactions of human membrane proteins
WO2015095410A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
WO2015171523A1 (en) 2014-05-05 2015-11-12 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
WO2015179835A2 (en) 2014-05-23 2015-11-26 Genentech, Inc. Mit biomarkers and methods using the same
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
WO2016011160A1 (en) 2014-07-15 2016-01-21 Genentech, Inc. Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
WO2016037157A2 (en) 2014-09-05 2016-03-10 The Johns Hopkins University Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
WO2016090300A1 (en) 2014-12-05 2016-06-09 Genentech, Inc. Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
US9428789B2 (en) 2011-03-21 2016-08-30 Biodesy, Inc. Classification of kinase inhibitors using nonlinear optical techniques
WO2016191397A1 (en) 2015-05-22 2016-12-01 Td2 Inc. Benzamide and active compound compositions and methods of use
WO2016205681A1 (en) 2015-06-19 2016-12-22 University Of Rochester Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
WO2017058780A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
WO2017079442A1 (en) 2015-11-04 2017-05-11 Icahn School Of Medicine At Mount Sinai Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
WO2017112955A1 (en) 2015-12-23 2017-06-29 Pharma Llc Moonshot Methods for inducing an immune response by inhibition of nonsense mediated decay
WO2017189730A1 (en) 2016-04-26 2017-11-02 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
WO2018098401A1 (en) 2016-11-23 2018-05-31 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
EP3360567A1 (en) 2007-11-07 2018-08-15 Genentech, Inc. Amp for use in treating microbial disorders
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
WO2018157027A1 (en) 2017-02-27 2018-08-30 Regeneron Pharmaceuticals, Inc. Humanized model of kidney and liver disorders
WO2018195472A1 (en) 2017-04-21 2018-10-25 Genentech, Inc. Use of klk5 antagonists for treatment of a disease
WO2018200742A1 (en) 2017-04-25 2018-11-01 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
WO2019126472A1 (en) 2017-12-22 2019-06-27 Genentech, Inc. Use of pilra binding agents for treatment of a disease
US10352936B2 (en) 2011-04-14 2019-07-16 Apoplogic Pharmaceuticals, Inc. Use of tumor Fas expression to determine response to anti-cancer therapy
US10376535B2 (en) 2015-03-26 2019-08-13 University Of Rochester Therapy for malignant disease
US10768174B2 (en) 2014-12-23 2020-09-08 Bluelight Therapeutics, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
WO2020239558A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
US10934261B2 (en) 2016-09-28 2021-03-02 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
EP3789036A1 (en) 2013-07-16 2021-03-10 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
EP3789402A1 (en) 2014-11-20 2021-03-10 F. Hoffmann-La Roche AG Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
US11292801B2 (en) 2016-07-05 2022-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
WO2022084210A1 (en) 2020-10-20 2022-04-28 F. Hoffmann-La Roche Ag Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
WO2022118197A1 (en) 2020-12-02 2022-06-09 Pfizer Inc. Time to resolution of axitinib-related adverse events
WO2022258600A1 (en) 2021-06-09 2022-12-15 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
WO2023057882A1 (en) 2021-10-05 2023-04-13 Pfizer Inc. Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
US11654135B2 (en) 2017-06-22 2023-05-23 Moonshot Pharma Llc Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0040922A1 (en) * 1980-05-12 1981-12-02 Biogen N.V. DNA sequences, recombinant DNA molecules and processes for producing polypeptides with the specificity of foot and mouth disease viral antigens
EP0048455A2 (en) * 1980-09-18 1982-03-31 The Wellcome Foundation Limited Synthetic DNA and process therefor
GB2103622A (en) * 1981-06-16 1983-02-23 Genentech Inc Production of foot and mouth disease vaccine from microbially expressed antigens
AU1255383A (en) * 1982-03-26 1983-09-29 Biogen N.V. Foot and mouth disease viral antigenic peptides
WO1983003547A1 (en) * 1982-04-14 1983-10-27 Bittle, James, L. Synthetic picornavirus antigen

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0040922A1 (en) * 1980-05-12 1981-12-02 Biogen N.V. DNA sequences, recombinant DNA molecules and processes for producing polypeptides with the specificity of foot and mouth disease viral antigens
EP0048455A2 (en) * 1980-09-18 1982-03-31 The Wellcome Foundation Limited Synthetic DNA and process therefor
GB2103622A (en) * 1981-06-16 1983-02-23 Genentech Inc Production of foot and mouth disease vaccine from microbially expressed antigens
AU1255383A (en) * 1982-03-26 1983-09-29 Biogen N.V. Foot and mouth disease viral antigenic peptides
WO1983003547A1 (en) * 1982-04-14 1983-10-27 Bittle, James, L. Synthetic picornavirus antigen

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Annales de Recherches Veterinaires, Volume 8, No. 1, issued 1977, BERNARD et al, "Comparison of the Immunosenic Potencies of Purified Inactivated Foot and Mouth Disease (Type O) Virus Patricles with Controlled Amounts of VPI Protein" see pages 79 to 94 *
Febs Letters, Volume 157, No. 2, issued July 1983, CLARKE et al. "Synthetic Peptides Mimic Subtype Specificity of Foot and Mouth Disease Virus", see pages 261 to 264 *
J. Gen. Virol, Volume 46, issued 1980, ROBSON et al, "Biochemical Aspects of Variation in Foot-and-Mouth Disease Virus" see pages 179 to 193 *
Journal of Virology, Volume 48, No. 2, issued November 1983, CHEUNG et al. "Comparison of the Major Antigenic Determinants of Different Serotypes of Foot and Mouth Disease Virus" see pages 451 to 459 *
Nature, Volume 290, issued 30 April 1981, BOOTHROYD et al., "Molecular Cloning of Foot and Mouth Disease Virus Genome and Nucleotide Sequences in the Structural Protein Genes", see pages 800 to 802 *
Nature, Volume 298, issued 1 July 1982, BITTLE et al. "Protection Against Foot and Mouth Disease by Immunization with a Chemically Synthesized Peptide Predicted from the Viral Necleotide Sequence", see pages 30 to 33 *
Nucleic Acids Research, Volume 9, No. 8, issued 1981, KURZ et al, "Nucleotide Sequence and Corresponding Amino Acid Sequence of the Gene for Major Antigen of Foot and Mouth Disease Virus", see pages 1919 to 1931 *
Scientific American, Volume 248, No. 2, issued February 1983, LERNER, "Synthetic Vaccines", see pages 48 to 56. *

Cited By (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114759A2 (en) * 1983-01-24 1984-08-01 Bruce Heywood Nicholson Amino acid sequences and polypeptides including these sequences and having the specificity of foot and mouth disease and other viral antigens
EP0114759A3 (en) * 1983-01-24 1987-09-02 Bruce Heywood Nicholson Amino acid sequences and polypeptides including these sequences and having the specificity of foot and mouth disease and other viral antigens
EP0138855A4 (en) * 1983-03-08 1986-02-10 Commw Serum Lab Commission Method of determining antigenically active amino acid sequences.
EP0138855A1 (en) * 1983-03-08 1985-05-02 Commw Serum Lab Commission Method of determining antigenically active amino acid sequences.
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US5063150A (en) * 1984-09-19 1991-11-05 The Regents Of The University Of California Retroviral polypeptides associated with human cellular transformation
EP0180564A2 (en) * 1984-11-01 1986-05-07 Bror Morein Immunogenic complex, a method for producing the same, and the use thereof as an immune stimulant, vaccines and reagents
US5254339A (en) * 1984-11-01 1993-10-19 Bror Morein Process for preparing immune complexes
EP0180564A3 (en) * 1984-11-01 1988-06-01 Bror Morein Immunogenic complex, a method for producing the same, and the use thereof as an immune stimulant, vaccines and reagents
WO1986006487A1 (en) 1985-04-22 1986-11-06 Commonwealth Serum Laboratories Commission Method for determining mimotopes
US5866363A (en) * 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
US6605448B1 (en) 1985-08-28 2003-08-12 George Pieczenik Method and means for sorting and identifying biological information
EP0226513A1 (en) * 1985-12-06 1987-06-24 Institut Pasteur Peptides capable of inhibiting interactions between antigens and lymphocytes T4, products derived therefrom and their applications
WO1987003601A1 (en) * 1985-12-06 1987-06-18 Institut Pasteur Peptides capable of inhibiting the interactions between antigens and lymphocytes t4, products derived therefrom and application thereof
FR2591227A1 (en) * 1985-12-06 1987-06-12 Pasteur Institut PEPTIDES CAPABLE OF INHIBITING INTERACTIONS BETWEEN LAV VIRUSES AND T4 LYMPHOCYTES, PRODUCTS DERIVED THEREFROM, AND APPLICATIONS THEREOF
FR2600335A1 (en) * 1986-06-19 1987-12-24 Pasteur Institut METHOD OF ANALYZING IMMUNOGENIC PEPTIDE SEQUENCES CARRYING A CHARACTERISTIC EPITOPE OF A FOREIGN PROTEIN WITH THE ORGANISM OF A LIVING HOST, FOR VACCINE PRODUCTION
US5593679A (en) * 1987-10-26 1997-01-14 Akzo Nobel N.V. Poultry vaccine against E. coli air sac inflammation and septicaemia
FR2631451A1 (en) * 1988-05-13 1989-11-17 Inst Nat Sante Rech Med Locating epitope(s) in protein reactive with monoclonal antibodies - by testing immuno-reactivity of truncated polypeptide(s) translated from fragments of C-DNA
US5286789A (en) * 1989-05-26 1994-02-15 Applied Immune Sciences, Inc. Solid phase multiple peptide synthesis
US5504190A (en) * 1990-11-21 1996-04-02 Torrey Pines Institute For Molecular Studies Equimolar multiple oligomer mixtures, especially oligopeptide mixtures
US5556762A (en) * 1990-11-21 1996-09-17 Houghten Pharmaceutical Inc. Scanning synthetic peptide combinatorial libraries: oligopeptide mixture sets having a one predetermined residue at a single, predetermined position, methods of making and using the same
US6197529B1 (en) 1990-11-21 2001-03-06 Torrey Pines Institute For Molecular Studies Linear substituted oligoalkyleneimine libraries
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US6649735B1 (en) 1992-03-06 2003-11-18 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US5891640A (en) * 1992-03-06 1999-04-06 N.V. Innogenetics S.A. Peptide derived from human immunodeficiency virus type 1 (HIV-1), isolate ant70, containing an immunodominant epitope and it's use in immunodiagnostic assays
US6165730A (en) * 1992-03-06 2000-12-26 N.V. Innogenetics S.A. Hepatitis C virus peptides obtained from the NS4 coding region and their use in diagnostic assays
US6210903B1 (en) 1992-03-06 2001-04-03 N. V. Innogenetics S. A. Peptide derived from human immunodeficiency virus type 1 (HIV-1), isolate Ant70, containing an immunodominant epitope and it's use in immunodiagnostic assays
WO1993018054A2 (en) * 1992-03-06 1993-09-16 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
WO1993018054A3 (en) * 1992-03-06 1994-02-17 Innogenetics Nv Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US5846731A (en) * 1993-06-17 1998-12-08 Torry Pines Institute For Molecular Studies Peralkylated oligopeptide mixtures
US5763193A (en) * 1993-06-17 1998-06-09 Torrey Pines Institute For Molecular Studies Peralkylated oligopeptide mixtures
US6287787B1 (en) 1993-11-24 2001-09-11 Torrey Pines Institute For Molecular Studies Dimeric oligopeptide mixture sets
US5645996A (en) * 1994-08-24 1997-07-08 Torrey Pines Institute For Molecular Studies Melittin-related polypeptides, mixture sets and libraries thereof
US5582997A (en) * 1994-08-24 1996-12-10 Torrey Pines Institute For Molecular Studies Lysine/leucine polypeptides, mixture sets and libraries thereof
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
US6933284B2 (en) 1998-03-10 2005-08-23 The Regents Of The University Of California Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding
US6579682B1 (en) 1998-03-10 2003-06-17 The Regents Of University Of California Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding
US7038011B2 (en) 1998-03-10 2006-05-02 The Regents Of The University Of California Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding
EP1992643A2 (en) 2001-06-20 2008-11-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2000545A1 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2000148A1 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of prostate cancer
EP2000482A1 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
EP2153843A1 (en) 2001-09-18 2010-02-17 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2151244A1 (en) 2001-09-18 2010-02-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2143438A1 (en) 2001-09-18 2010-01-13 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2067472A1 (en) 2002-01-02 2009-06-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003066672A1 (en) * 2002-02-08 2003-08-14 Nakoshi, Hideo Peptides
EP2011886A2 (en) 2002-04-16 2009-01-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2083018A2 (en) 2003-04-16 2009-07-29 Genentech, Inc. Compositions and methods relating to STOP-1
EP2784084A1 (en) 2003-07-08 2014-10-01 Genentech, Inc. IL-17 A/F heterologous polypeptides and therapeutics uses thereof
EP3594228A1 (en) 2003-07-08 2020-01-15 Genentech, Inc. Il-17a/f heterologous polypedtides and therapeutic uses thereof
EP2277908A2 (en) 2003-07-08 2011-01-26 Genentech, Inc. IL-17A/F heterologous polypeptides, antibodies and therapeutic uses thereof
EP2161283A1 (en) 2003-11-17 2010-03-10 Genentech, Inc. Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or cytotoxic agent and methods for the treatment of tumor of hematopoietic origin
EP2301568A1 (en) 2003-11-17 2011-03-30 Genentech, Inc. Antibody against IRTA2 for the treatment of tumour of hematopoietic origin
EP2295073A1 (en) 2003-11-17 2011-03-16 Genentech, Inc. Antibody against CD22 for the treatment of tumour of hematopoietic origin
EP2050763A2 (en) 2005-03-10 2009-04-22 Genentech, Inc. Methods and compositions for modulating vascular integrity
EP2186402A1 (en) 2005-06-06 2010-05-19 Genentech, Inc. Knock-out animal models for novel genes and methods of use
EP1995321A2 (en) 2005-08-15 2008-11-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP2002714A1 (en) 2005-11-21 2008-12-17 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP3006466A2 (en) 2005-12-02 2016-04-13 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
EP2623516A2 (en) 2005-12-02 2013-08-07 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
WO2007126439A2 (en) 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
EP2050335A1 (en) 2006-02-17 2009-04-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP2614839A2 (en) 2006-04-05 2013-07-17 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP2520935A2 (en) 2006-08-09 2012-11-07 Homestead Clinical Corporation Organ-specific proteins and methods of their use
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
EP2386655A2 (en) 2006-09-12 2011-11-16 Genentech, Inc. Methods and compositions for the diagnosis and treatment of lung cancer using KIT or KDG gene as genetic marker
EP2845912A1 (en) 2006-09-12 2015-03-11 Genentech, Inc. Methods and compositions for the diagnosis and treatment of lung cancer using KIT gene as genetic marker
EP3181147A1 (en) 2006-11-29 2017-06-21 Genentech, Inc. Il-17a/f heterodimeric polypeptides and therapeutic thereof
EP2450050A1 (en) 2006-11-29 2012-05-09 Genentech, Inc. IL-17A/F heterodimeric polypeptides and therapeutic uses thereof
WO2008067223A2 (en) 2006-11-29 2008-06-05 Genentech, Inc. Il-17a/f heterodimeric polypeptides and therapeutic uses thereof
EP2436781A1 (en) 2007-02-22 2012-04-04 Genentech, Inc. Methods for detecting inflammatory bowel disease
WO2008103962A2 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
US8309351B2 (en) 2007-10-04 2012-11-13 Bionomics Limited Methods of identifying agents that inhibit angiogenesis
EP3360567A1 (en) 2007-11-07 2018-08-15 Genentech, Inc. Amp for use in treating microbial disorders
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
US9880172B2 (en) 2008-08-04 2018-01-30 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
EP3929216A1 (en) 2008-12-09 2021-12-29 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP4169951A1 (en) 2008-12-09 2023-04-26 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP4209510A1 (en) 2008-12-09 2023-07-12 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
EP4331604A2 (en) 2008-12-09 2024-03-06 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2011026200A2 (en) 2009-09-02 2011-03-10 Katholieke Universiteit Leuven New methods for diagnosing autoimmune diseases
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
US9885711B2 (en) 2009-09-25 2018-02-06 Xoma Technology Ltd. Screening methods
EP3187877A1 (en) 2009-09-25 2017-07-05 XOMA Technology Ltd. Screening methods
WO2011050194A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
US8697386B2 (en) 2009-10-22 2014-04-15 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011066503A2 (en) 2009-11-30 2011-06-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP3002297A2 (en) 2009-11-30 2016-04-06 F. Hoffmann-La Roche AG Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211)
WO2011103242A1 (en) 2010-02-18 2011-08-25 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011106297A2 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2011139985A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
US9428789B2 (en) 2011-03-21 2016-08-30 Biodesy, Inc. Classification of kinase inhibitors using nonlinear optical techniques
US10352936B2 (en) 2011-04-14 2019-07-16 Apoplogic Pharmaceuticals, Inc. Use of tumor Fas expression to determine response to anti-cancer therapy
US10646567B2 (en) 2011-08-01 2020-05-12 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
US9724413B2 (en) 2011-08-01 2017-08-08 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
WO2013019906A1 (en) 2011-08-01 2013-02-07 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
WO2013040433A1 (en) 2011-09-15 2013-03-21 Genentech, Inc. Methods of promoting differentiation
WO2013056148A2 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
WO2013109856A2 (en) 2012-01-18 2013-07-25 Genentech, Inc. Methods of using fgf19 modulators
WO2013120056A1 (en) 2012-02-11 2013-08-15 Genentech, Inc. R-spondin translocations and methods using the same
WO2013135745A1 (en) 2012-03-16 2013-09-19 F. Hoffmann-La Roche Ag Methods of treating melanoma with pak1 inhibitors
WO2013137920A1 (en) 2012-03-16 2013-09-19 Genentech, Inc. Engineered conformationally-stabilized proteins
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
WO2013162654A1 (en) 2012-04-25 2013-10-31 Biodesy, Llc Methods for detecting allosteric modulators of proteins
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
EP3556776A1 (en) 2012-05-31 2019-10-23 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonists and vegf antagonists
WO2013181452A1 (en) 2012-05-31 2013-12-05 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
WO2014138364A2 (en) 2013-03-06 2014-09-12 Genentech, Inc. Methods of treating and preventing cancer drug resistance
WO2014153030A2 (en) 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
WO2014151006A2 (en) 2013-03-15 2014-09-25 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
US10584155B2 (en) 2013-03-15 2020-03-10 Genentech, Inc. Pharmaceutical compositions of IL-22 Fc fusion proteins
US11155591B2 (en) 2013-03-15 2021-10-26 Genentech, Inc. Methods of treating acute pancreatitis using IL-22 fc fusion proteins
US11136365B2 (en) 2013-03-15 2021-10-05 Genentech, Inc. Methods for preventing or treating cardiovascular conditions using il-22 fc fusion proteins
US11130791B2 (en) 2013-03-15 2021-09-28 Genentech, Inc. Methods for treating metabolic syndrome using IL-22 Fc fusion proteins
US10160793B2 (en) 2013-03-15 2018-12-25 Genentech, Inc. Methods of treating inflammatory bowel disease using IL-22 Fc fusion proteins
US11332507B2 (en) 2013-03-15 2022-05-17 Genentech, Inc. IL-22 Fc fusion proteins
EP3633377A1 (en) 2013-03-15 2020-04-08 F. Hoffmann-La Roche AG Biomarkers and methods of treating pd-1 and pd-l1 related conditions
US9815880B2 (en) 2013-03-15 2017-11-14 Genentech, Inc. IL-22 Fc fusion proteins
EP3385277A1 (en) 2013-03-15 2018-10-10 F. Hoffmann-La Roche AG Il-22 polypeptides and il-22 fc fusion proteins and methods of use
US10544198B2 (en) 2013-03-15 2020-01-28 Genentech, Inc. Methods of accelerating or improving wound healing using IL-22 FC fusion proteins
US10087227B2 (en) 2013-03-15 2018-10-02 Genentech, Inc. Nucleic acids encoding IL-22 Fc fusion proteins
EP4356960A2 (en) 2013-03-15 2024-04-24 F. Hoffmann-La Roche AG Biomarkers and methods of treating pd-1 and pd-l1 related conditions
WO2014144850A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
WO2014145016A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
US10208290B2 (en) 2013-06-21 2019-02-19 The Johns Hopkins University Virion display array for profiling functions and interactions of human membrane proteins
WO2014205344A2 (en) 2013-06-21 2014-12-24 The Johns Hopkins University Virion display array for profiling functions and interactions of human membrane proteins
EP3789036A1 (en) 2013-07-16 2021-03-10 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
WO2015095410A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
WO2015171523A1 (en) 2014-05-05 2015-11-12 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
EP4317445A2 (en) 2014-05-05 2024-02-07 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
EP3636073A1 (en) 2014-05-05 2020-04-15 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
US11178860B2 (en) 2014-05-05 2021-11-23 Regeneron Pharmaceuticals, Inc. Humanized C5 animals
US9795121B2 (en) 2014-05-05 2017-10-24 Regeneron Pharmaceuticals, Inc. Humanized C3 animals
US10492477B2 (en) 2014-05-05 2019-12-03 Regeneron Pharmaceuticals, Inc. Humanized C5 animals
US10524458B2 (en) 2014-05-05 2020-01-07 Regeneron Pharmaceuticals, Inc. Humanized C3 animals
WO2015179835A2 (en) 2014-05-23 2015-11-26 Genentech, Inc. Mit biomarkers and methods using the same
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
US10946093B2 (en) 2014-07-15 2021-03-16 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
WO2016011160A1 (en) 2014-07-15 2016-01-21 Genentech, Inc. Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
EP3563870A1 (en) 2014-07-15 2019-11-06 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
WO2016037157A2 (en) 2014-09-05 2016-03-10 The Johns Hopkins University Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
US11219670B2 (en) 2014-09-05 2022-01-11 The Johns Hopkins University Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
EP3789402A1 (en) 2014-11-20 2021-03-10 F. Hoffmann-La Roche AG Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
EP4141032A1 (en) 2014-11-20 2023-03-01 F. Hoffmann-La Roche AG Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
WO2016090300A1 (en) 2014-12-05 2016-06-09 Genentech, Inc. Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
US10768174B2 (en) 2014-12-23 2020-09-08 Bluelight Therapeutics, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
US10376535B2 (en) 2015-03-26 2019-08-13 University Of Rochester Therapy for malignant disease
EP3718569A1 (en) 2015-05-22 2020-10-07 Translational Drug Development, LLC Benzamide and active compound compositions and methods of use
WO2016191397A1 (en) 2015-05-22 2016-12-01 Td2 Inc. Benzamide and active compound compositions and methods of use
EP4209228A1 (en) 2015-05-22 2023-07-12 Translational Drug Development, LLC Benzamide and active compound compositions and methods of use
WO2016205681A1 (en) 2015-06-19 2016-12-22 University Of Rochester Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
WO2017058780A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
WO2017079442A1 (en) 2015-11-04 2017-05-11 Icahn School Of Medicine At Mount Sinai Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
US10898483B2 (en) 2015-12-23 2021-01-26 Moonshot Pharma Llc Methods for inducing an immune response by promoting premature termination codon read-through
US11957678B2 (en) 2015-12-23 2024-04-16 Moonshot Pharma Llc Methods for inducing an immune response
US10966976B2 (en) 2015-12-23 2021-04-06 Moonshot Pharma Llc Methods for inducing an immune response by inhibition of nonsense mediated decay
WO2017112956A1 (en) 2015-12-23 2017-06-29 Moonshot Pharma Llc Methods for inducing an immune response
US11135221B2 (en) 2015-12-23 2021-10-05 Moonshot Pharma Llc Methods for inducing an immune response
WO2017112955A1 (en) 2015-12-23 2017-06-29 Pharma Llc Moonshot Methods for inducing an immune response by inhibition of nonsense mediated decay
WO2017189730A1 (en) 2016-04-26 2017-11-02 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
US11292801B2 (en) 2016-07-05 2022-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
US10934261B2 (en) 2016-09-28 2021-03-02 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
US11339130B1 (en) 2016-09-28 2022-05-24 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
WO2018098401A1 (en) 2016-11-23 2018-05-31 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
WO2018157027A1 (en) 2017-02-27 2018-08-30 Regeneron Pharmaceuticals, Inc. Humanized model of kidney and liver disorders
WO2018195472A1 (en) 2017-04-21 2018-10-25 Genentech, Inc. Use of klk5 antagonists for treatment of a disease
WO2018200742A1 (en) 2017-04-25 2018-11-01 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
EP4230649A2 (en) 2017-04-25 2023-08-23 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
US11654135B2 (en) 2017-06-22 2023-05-23 Moonshot Pharma Llc Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
WO2019126472A1 (en) 2017-12-22 2019-06-27 Genentech, Inc. Use of pilra binding agents for treatment of a disease
WO2020239558A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
WO2022084210A1 (en) 2020-10-20 2022-04-28 F. Hoffmann-La Roche Ag Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
WO2022118197A1 (en) 2020-12-02 2022-06-09 Pfizer Inc. Time to resolution of axitinib-related adverse events
WO2022258600A1 (en) 2021-06-09 2022-12-15 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
WO2023057882A1 (en) 2021-10-05 2023-04-13 Pfizer Inc. Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer

Similar Documents

Publication Publication Date Title
EP0138854B1 (en) Antigenically active amino acid sequences
WO1984003506A1 (en) Antigenically active amino acid sequences
EP0138855B1 (en) Method of determining antigenically active amino acid sequences
Geysen et al. Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid.
Bittle et al. Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence
KR100257941B1 (en) Process for the determination of peptides corresponding to immunologically important epitopes and biotinylated peptides used therein
US5574132A (en) Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
Schaaper et al. Manipulation of antipeptide immune response by varying the coupling of the peptide with the carrier protein
Schoofs et al. Epitopes of an influenza viral peptide recognized by antibody at single amino acid resolution.
US5229491A (en) Peptides immunochemically reactive with antibodies directed against hepatitis non-a, non-b virus
AU654240B2 (en) A method of eliciting the production of antibodies against HTLV-1 in mammals
KR100523972B1 (en) Epstein-Barrvirus Peptides and Antibodies Against These Peptides
JPH01224397A (en) Synthetic peptide for detecting hiv antibody and mixture thereof
Saiz et al. Antigenic comparison of different foot-and-mouth disease vims types using monoclonal antibodies defining multiple neutralizing epitopes on FMDV A5 subtypes
EP1622932A2 (en) Peptides and mixtures thereof for use in the detection of severe acute respiratory syndrome-associated coronavirus (sars)
EP0479376B1 (en) Peptides immunochemically reactive with antibodies directed against hepatitis Non-A, Non-B virus
Fischer et al. Synthetic peptide antigens of tetanus toxin
JPH05331193A (en) Peptide reacting immunochemically with antibody to non-a non-b hepatitis virus
US6218102B1 (en) Synthetic peptides and mixtures thereof for detecting HIV antibodies
JPH04221398A (en) Antibody to non-a, non-b hepatitis virus and immunochemically reactive peptide

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): DK JP NO US

AL Designated countries for regional patents

Designated state(s): AT BE CH DE FR GB LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1984900954

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1984900954

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1984900954

Country of ref document: EP